Gene: PLCXD1
Official Full Name: phosphatidylinositol specific phospholipase C X domain containing 1provided by HGNC
Gene Summary: This gene is the most terminal protein-coding gene in the pseudoautosomal (PAR) region on chromosomes X and Y. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Mar 2010]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO15093 | PLCXD1 Knockout cell line (HeLa) | Human | PLCXD1 | 1:3~1:6 | Negative | Online Inquiry |
KO15094 | PLCXD1 Knockout cell line (HCT 116) | Human | PLCXD1 | 1:2~1:4 | Negative | Online Inquiry |
KO15095 | PLCXD1 Knockout cell line (HEK293) | Human | PLCXD1 | 1:3~1:6 | Negative | Online Inquiry |
KO15096 | PLCXD1 Knockout cell line (A549) | Human | PLCXD1 | 1:3~1:4 | Negative | Online Inquiry |
PLCXD1 Gene Knockout Cell Lines are specialized cellular models engineered to lack the expression of the PLCXD1 gene. This gene is known for its role in phospholipid signaling pathways, influencing various cellular processes such as cell proliferation and differentiation. By utilizing CRISPR/Cas9 technology, these knockout cell lines provide a reliable system for studying the biological implications of PLCXD1 disruption, enabling researchers to elucidate its function in health and disease.
The key function of PLCXD1 in cellular signaling involves the regulation of phosphoinositide metabolism, which ultimately affects cytoskeletal dynamics, membrane trafficking, and cellular response to external stimuli. The knockout design permits a robust analysis of the functional consequences of PLCXD1 loss, facilitating experiments that probe into its involvement in cancer, neurodegenerative disorders, and other pathologies where phosphoinositide signal transduction may be altered.
In both research and clinical applications, these cell lines serve as crucial tools for drug screening, biomarker discovery, and the validation of therapeutic targets. By providing insights into PLCXD1-related pathways, scientists can better understand disease mechanisms and identify novel intervention strategies. The precise and reproducible nature of these knockout lines distinguishes them from traditional models, offering a level of specificity that enhances experimental accuracy.
One of the unique selling points of PLCXD1 Gene Knockout Cell Lines is their ability to provide a consistent experimental platform, which is crucial for achieving reliable results across different studies. Furthermore, the time-saving benefits of having pre-engineered cell lines alleviate the need for labor-intensive gene-editing processes, allowing researchers to focus on downstream analyses.
For researchers and clinicians aiming to advance their understanding of signaling pathways, PLCXD1 Gene Knockout Cell Lines are an invaluable asset. The meticulous development and validation underpinning this product ensure that users receive a premium research tool designed to facilitate groundbreaking discoveries. Our company prides itself on its expertise in biotechnological innovations, delivering high-quality products that empower advancements in biological research and therapeutic development.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.